This suggests that high TIM3 expression may help tumors enhance Gal-9 expression on CD4+ T cells, making it a potential target for immunotherapies aimed at blocking these molecules to effectively treat patients with HPV-associated cancers [59]. This evidence concerns the gene HAVCR2 and cancer.